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Objectives. This study sought to compare the incidence of early
cerebrovascular events and subsequent mortality in two cohorts of
consecutive patients with acute myocardial infarction (AMI),
admitted to coronary care units (CCUs) in Israel, in the pre-
thrombolytic and thrombolytic eras.
Background. During the past decade, substantial changes have
occurred in the medical treatment of AMI, and important new
therapies have been introduced that could all affect stroke risk
and type by diverse mechanisms. Yet the overall impact of these
new therapeutic modalities on the incidence of stroke complicat-
ing AMI is not clear.
Methods. We compared the incidence and mortality rates of
cerebrovascular events complicating AMI within CCUs among
5,839 consecutive patients admitted in the period 1981 to 1983
versus 2,012 patients from two prospective nationwide surveys
conducted in all CCUs operating in Israel in 1992 and 1994.
Results. The demographic and clinical characteristics of pa-
tients with AMI in both periods were comparable. Patients
admitted in the period 1981 to 1983 did not receive thrombolysis
and reperfusion therapy; those admitted in 1992 and 1994 re-
ceived thrombolysis (45%) and coronary angioplasty or coronary
artery bypass graft surgery (14%), and antiplatelet and anticoag-
ulant treatments were more frequently used. The incidence of
early cerebrovascular events was 0.74% (43 of 5,839) in 1981 to
1983 versus 0.75% (15 of 2,012) in the 1992 to 1994 cohort.
Patients with an AMI who experienced a cerebrovascular event
were somewhat older in both groups and had a high rate of
previous cerebrovascular events, congestive heart failure and
atrial and ventricular arrhythmias during the hospital period.
Mortality declined by one-third between the two periods. However,
the mortality rate of patients with AMI who sustained a cerebro-
vascular event remained high (>240% for 30 days, 60% for 1 year).
Conclusions. The overall incidence of early cerebrovascular
events complicating AMI remained similar (0.75%) in the pre-
thrombolytic and thrombolytic eras. Mortality rates of patients
with an AMI but no cerebrovascular events decreased substan-
tially over the past decade but not in patients with AMI with a
cerebrovascular event.
(J Am Coll Cardiol 1997;30:1484–90)
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Stroke is a well known, potentially catastrophic complication of
acute myocardial infarction (AMI). Before the advent of
thrombolysis, the reported incidence of stroke in the acute
phase of the infarction varied between 0.8% and 5.5% (1–4).
Most strokes were considered to be cardioembolic, as indi-
cated by their association with large anterior myocardial
infarctions and left ventricular thrombi detected by echocardi-
ography.
Over the past decade, the management of AMI has changed
dramatically and includes improved medical treatment, throm-
bolytic therapy and mechanical revascularization. These ther-
apeutic modalities may affect the rate and type of stroke by
diverse mechanisms. However, the overall impact of these
changes in therapy on the incidence of stroke complicating
AMI in an unselected postinfarction population is not clear.
Valuable information on overall stroke incidence, type and
functional outcome after thrombolytic therapy for AMI was
provided by the large comparative trials of thrombolytic
agents, and, in particular, the Global Utilization of Streptoki-
nase and Tissue Plasminogen Activator for Occluded Coronary
Arteries (GUSTO-1) megatrial (5–8). These and other recent
trials have suggested that effective use of thrombolytic therapy
has been accompanied by more intracranial hemorrhages and
slightly less ischemic strokes (9–11). Yet data in the thrombo-
lytic era are mostly derived from clinical trials in which selected
patients receive thrombolysis under strict protocols that ex-
clude high risk patients. Moreover, wide methodologic varia-
tions complicate any comparison with studies conducted in the
prethrombolytic era.
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The aim of the present study was to compare the incidence
and mortality from early cerebrovascular events in two large
cohorts of consecutive patients with an AMI admitted to
coronary care units (CCUs) in Israel, one during 1981 to 1983
(prethrombolytic era), and the other during 1992 and 1994
(thrombolytic era).
Methods
This report analyzed data from two cohorts of consecutive
patients admitted to CCUs in Israel with a diagnosis of AMI.
The first cohort (Secondary Prevention Reinfarction Israeli
Nifedipine Trial [SPRINT] registry [12]) included 5,839 con-
secutive patients with an AMI admitted to 13 CCUs in Israel
between August 1981 and July 1983. Thrombolysis was not
provided to any patient in this cohort. The second cohort was
derived from two prospective national surveys conducted dur-
ing 2-month periods (January and February) in 1992 and 1994,
respectively, and included 2,012 consecutive patients with a
confirmed AMI admitted to all 25 operating CCUs in Israel.
During the survey of 1992 (n 5 1,012), all CCUs followed
uniform guidelines for thrombolytic treatment because all
participated in the international GUSTO-1 trial (7). Patients
ineligible for the GUSTO-1 trial who did not receive throm-
bolytic therapy or who nevertheless received thrombolytic
therapy at the discretion of the treating physician and patients
who underwent mechanical reperfusion (percutaneous trans-
luminal coronary angioplasty [PTCA] or coronary artery by-
pass graft surgery [CABG]) were all included in the survey. In
1994 (n 5 1,000), thrombolytic therapy and invasive proce-
dures were utilized at the discretion of each center. Both
cohorts in the 1980s and 1990s included all consecutive pa-
tients with an AMI admitted to the CCUs during the respective
designated time periods, and both cohorts included patients on
hospital admission.
Demographic and clinical data were recorded for all regis-
tered patients with an AMI in both cohorts by study physicians
in the CCUs. Historical characteristics were based on self-
report by patients at the time of hospital admission. Identical
criteria were used in both cohorts for diagnosis of AMI and
stroke. Diagnosis of AMI was based on the presence of any two
of the following: typical chest pain lasting at least 30 min,
unequivocal new electrocardiographic changes (Q/QS or ST
segment and T wave changes, or both); or an increase of at
least two of the serum cardiac enzymes (creatine kinase,
glutamic oxaloacetic transaminase and lactate dehydrogenase)
to .1.5 times the upper limit or a concomitant increase in
creatine kinase-MB isoenzyme. The diagnosis of a cerebrovas-
cular event was based on rapidly developing clinical signs of
focal neurologic deficit. Ischemic strokes and intracerebral
hemorrhages were differentiated by brain imaging, when avail-
able, in the 1992 to 1994 period. No attempt was made to
differentiate stroke types in the 1981 to 1983 period because
brain imaging was less available and seldom performed during
that period.
Data were analyzed at the same coordinating center, and
individual records of all reported cerebrovascular cases from
both cohorts were reviewed by the same investigator (D.T.).
Rates of cerebrovascular events from day of admission and
within CCUs (early cerebrovascular events) were compared
between the two cohorts. Mortality follow-up of at least 1 year
duration after hospital discharge was conducted in both co-
horts, with information available for 5,781 patients (99%) in
the 1981 to 1983 period and for 1,940 patients (96%) in the
1992 to 1994 cohort.
Statistical analysis. All analyses were performed using
SAS statistical software (13). Chi-square and t tests were used
to determine the significance of the differences between pro-
portions and mean values, respectively, where appropriate.
Results of continuous variables are reported as mean value 6
SD. Two-sided p values are reported.
The pooled Mantel-Haenszel relative risk was used to
compare mortality in the 1992 to 1994 versus 1981 to 1983
periods (where mortality in the 1981 to 1983 period was the
reference group) controlling for age, gender, diabetes mellitus,
hypertension, anginal syndrome, previous myocardial infarc-
tion, congestive heart failure on admission and anterior site of
myocardial infarction. Survival curves were estimated using the
Kaplan-Meier method.
Results
The baseline characteristics and in-hospital complications
and procedures for the two periods for all AMI patients and
for patients sustaining an early cerebrovascular event are
presented in Table 1.
Patient characteristics. The demographic and clinical
characteristics of the two cohorts of patients with AMI in the
two periods were comparable. The mean age and proportion of
men were similar. In the 1992 to 1994 period, the prevalence of
current smoking, diabetes mellitus, previous cerebrovascular
event and MI were somewhat higher, and the prevalence of
anginal syndrome was lower. The proportion of patients with
hypertension and an anterior location of the index AMI was
similar during both periods. Patients in the 1992 to 1994 period
had less congestive heart failure on admission and fewer
in-hospital complications, including ventricular tachycardia or
fibrillation, paroxysmal atrial fibrillation and congestive heart
failure. Patients sustaining a cerebrovascular event after AMI
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CABG 5 coronary artery bypass graft surgery
CCU 5 coronary care unit
GUSTO-I 5 Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary
Arteries
PTCA 5 percutaneous transluminal coronary angioplasty
SPRINT 5 Secondary Prevention Reinfarction Israeli Nifedipine
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were somewhat older in both cohorts and had a higher rate of
a previous cerebrovascular event, congestive heart failure and
atrial and ventricular arrhythmias during the hospital period
(Table 1).
Management. Major changes in patient management oc-
curred between the two periods. Whereas in the 1981 to 1983
period, thrombolytic therapy was not provided, and coronary
angiography, PTCA and CABG were almost not performed, in
the 1992 to 1994 period, thrombolysis was provided in 909
patients (45%), coronary angiography in 515 (26%) and PTCA
or CABG in 282 (14%) during the index hospital period (Table
1). During the 1992 to 1994 period, aspirin therapy was
provided in 1,570 patients (78%), anticoagulation in 923 (46%)
and beta-adrenergic blocking agents in 752 (37%). Data for
in-hospital medications during the 1981 to 1983 period are
lacking. Among patients discharged alive during the 1981 to
1983 period, aspirin was provided in 147 (3%), dipyridamole in
683 (14%), anticoagulant agents in 85 (2%) and beta-blockers
in 852 (18%).
Incidence. The overall incidence of cerebrovascular events
complicating AMI in the two cohorts are presented in Table 2.
Incidence of early cerebrovascular events (within CCUs) was
similar in both periods: 0.74% (43 of 5,839 patients) for the
1981 to 1983 period versus 0.75% (15 of 2,012 patients) for the
1992 to 1994 period. The incidence of cerebrovascular events
during the entire hospital period, available for the 1981 to 1983
but not the 1992 to 1994 cohort, was 0.92% (54 of 5,839
patients). Brain imaging results were available for 8 of 15
patients with stroke in the 1992 to 1994 period. In all eight
patients, brain imaging results were compatible with an isch-
emic stroke, with secondary hemorrhagic transformation in
two. In the other seven patients without brain imaging or
autopsy, strokes were regarded to be of undetermined origin,
and the number of parenchymatous intracerebral hemorrhages
among them is not known. Intravenous heparin before the
cerebrovascular event was provided in 1 of the 43 patients who
sustained a cerebrovascular event during the 1981 to 1983
period and in 6 of the 15 patients in the 1992 to 1994 period.
None of the cerebrovascular events were suspected by the
treating physician to be secondary or due to excessive antico-
agulation. In the 1992 to 1994 period, stroke occurred in nine
patients (1%) treated with thrombolysis (eight with streptoki-
nase, one with streptokinase and tissue-type plasminogen
activator) versus six (0.5%) patients with no thrombolysis. Left
ventricular thrombi were demonstrated by transthoracic echo-
cardiography in one-third (5 of 15) of patients with stroke, and
an additional stroke was associated with coronary angiography.
Mortality. Table 3 demonstrates the cumulative mortality
in 1981 to 1983 versus the 1992 to 1994 period for all patients
Table 1. Baseline Characteristics of the 1981 to 1983 Versus 1992 to 1994 Cohorts for All Patients
With Acute Myocardial Infarction and Patients With Early Cerebrovascular Events
All Patients With AMI Cerebrovascular Events
1981–1983
(n 5 5,839)
1992–1994
(n 5 2,012) p Value
1981–1983
(n 5 43)
1992–1994
(n 5 15) p Value
Age (yr) 63 6 11 63 6 12 NS 69 6 8 66 6 10 NS
Men 4,315 (74) 1,489 (74) NS 31 (78) 9 (60) NS
Patient history
Hypertension 2,314 (40) 787 (39) NS 18 (46) 6 (40) NS
Current smoking 1,850 (32) 737 (37) 0.001 10 (23) 5 (33) NS
Prior cerebrovascular event 272 (5) 115 (6) 0.075 11 (26) 3 (20) NS
Diabetes 1,208 (21) 515 (26) 0.001 10 (23) 6 (40) NS
Prior MI 1,415 (24) 572 (29) 0.001 9 (21) 7 (47) NS
Angina 2,868 (51) 565 (28) 0.001 18 (45) 5 (33) NS
Anterior site of MI 273 (47) 920 (46) NS 23 (53) 7 (47) NS
Congestive heart failure on admission 1,944 (33) 600 (30) 0.004 26 (60) 8 (53) NS
In-hospital complications
Ventricular tachycardia/fibrillation 1,274 (22) 223 (11) 0.001 12 (28) 5 (33) NS
Paroxysmal atrial fibrillation 751 (13) 192 (10) 0.001 16 (37) 6 (40) NS
Congestive heart failure or shock 1,545 (26) 420 (21) 0.001 19 (44) 6 (40) NS
In-hospital procedures
Thrombolysis — 909 (45) — 9 (60)
Coronary angiography 47 (1) 515 (26) — 2 (13)
PTCA/CABG 3 (0.05) 282 (14) — 0 (0)
Data presented are mean value 6 SD or number (%) of patients. AMI 5 acute myocardial infarction; MI 5
myocardial infarction; PTCA/CABG 5 percutaneous transluminal coronary angioplasty or coronary artery bypass graft
surgery; — 5 not performed.
Table 2. Overall Incidence of Cerebrovascular Events Complicating
Acute Myocardial Infarction
1981–1983
(n 5 5,839)
1992–1994
(n 5 2,012)
In CCUs 0.74% (43/5,839) 0.75% (15/2,012)
In-hospital 0.92% (54/5,839) NA
CCUs 5 coronary care units; NA 5 not available.
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with AMI and for patients with an early cerebrovascular event.
Mortality rates for all patients with AMI declined substantially
from the 1981 to 1983 period to the 1992 to 1994 period. The
7-day, 30-day and 1-year mortality rates decreased from 13%,
19% and 27% during 1981 to 1983 to 8%, 13% and 19%,
respectively, during 1992 to 1994. After multivariate analysis
adjusting for age and possible confounding variables (see
Methods), the covariate adjusted risk reduction in the 1992 to
1994 versus the 1981 to 1983 period was of the magnitude of
30% for 7-day, 30-day and 1-year cumulative mortality rates.
Mortality rates of patients sustaining an early cerebrovas-
cular event during AMI were high during both periods, with
30-day and 1-year mortality rates of $40% and 60%, respec-
tively (Table 3). Kaplan-Meier survival curves for patients with
early cerebrovascular events during the two periods are de-
picted in Figure 1.
Discussion
The main finding of this report is that the overall incidence of
early cerebrovascular events complicating AMI did not change
in our two consecutive cohorts of patients with AMI admitted
to CCUs in the early 1980s and early 1990s. During that period,
major changes in management took place, and subsequently,
the outcome after AMI improved substantially. However,
mortality rates of patients sustaining a cerebrovascular event
remained high during both periods.
Incidence of stroke in the prethrombolytic era. The re-
ported incidence of stroke complicating AMI in the prethrom-
bolytic era varied mostly between 0.8% and 5.5% (1–4).
Although brain imaging was not available, the occurrence of
intracranial hemorrhage seemed exceedingly rare, and most
strokes were attributed to cerebral embolism. An apparent
reduction in the incidence of stroke complicating AMI in
recent decades was noted in a meta-analysis (14), but hetero-
geneity among the trials complicated the interpretation of this
trend.
Changes in management of AMI. The management of
AMI changed substantially between the early 1980s and early
1990s, as shown in the present study. New therapies were
introduced for AMI, specifically thrombolysis and other reper-
fusion therapies (immediate PTCA and CABG). Other medi-
cal therapies, such as aspirin, beta-blockers, angiotensin-
converting enzyme inhibitors and heparin, gained widespread
use. In the 1992 to 1994 period, thrombolytic therapy was
provided in nearly 50% of patients; other reperfusion strate-
gies were often utilized; and antiplatelet and anticoagulant
treatments were provided in high rates. Indeed, these changes
were associated with a substantial reduction in cumulative
mortality rates of patients with AMI compared with those
during the 1981 to 1983 period.
These changes in the management of AMI may affect
stroke rates and types by diverse mechanisms. Aspirin reduced
the risk of early ischemic stroke by half in the Second
International Study of Infarct Survival (ISIS-2) trial (10).
Anticoagulation may decrease the risk of left ventricular
thrombi in patients with anterior site AMI and may be effective
in reducing the risk of embolic strokes in those with left
ventricular thrombi (15,16) but is associated with an increased
rate of intracranial hemorrhage. The higher than anticipated
rate of intracranial hemorrhage among patients treated with
heparin versus hirudin in conjunction with thrombolysis in the
GUSTO-IIa (17), TIMI-9A (18), and HIT-III (19) trials em-
Figure 1. One-year survival curves of patients with AMI with early
cerebrovascular events in the 1981 to 1983 versus 1992 to 1994 cohorts.
Table 3. Mortality Rates in 1981 to 1983 Versus 1992 to 1994 Cohorts for All Patients With Acute
Myocardial Infarction and Patients With Early Cerebrovascular Events
All Patients With AMI
Adjusted RR‡
(95% CI)
Cerebrovascular Events
1981–1983
(n 5 5,839)
1992–1994
(n 5 1,940)*
p
Value†
1981–1983
(n 5 43)
1992–1994
(n 5 15)
p
Value†
7-d mortality 13% (732) 8% (160) 0.001 0.72 (0.60–0.86) 35% (15) 20% (3) NS
30-d mortality 19% (1,097) 13% (258) 0.001 0.70 (0.61–0.81) 53% (23) 40% (6) NS
1-yr mortality 27% (1,563) 19% (370) 0.001 0.73 (0.68–0.81) 60% (26) 60% (9) NS
*Data regarding mortality follow-up available for 1,940 of 2,012 patients in the 1992 to 1994 cohort. †Univariate
analysis, 1981 to 1983 versus 1992 to 1994. ‡Comparison of the risk of dying between the two periods (1981 to 1983
reference group, relative risk [RR] 5 1) after adjusting for age, gender, diabetes mellitus, hypertension, anginal
syndrome, previous myocardial infarction, congestive heart failure on admission and anterior location of myocardial
infarction. AMI 5 acute myocardial infarction; CI 5 confidence interval; d 5 day.
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phasizes the risks of more potent anticoagulation in combina-
tion with thrombolysis and the narrow therapeutic/toxic ratio.
The main fear from thrombolytic therapy after AMI is the
development of a major hemorrhagic complication, especially
an intracranial hemorrhage. After thrombolysis, a shift in type
of strokes was demonstrated: more intracranial hemorrhages
albeit somewhat less ischemic strokes (9–11). Thrombolytic
therapy was shown (15,16) to reduce the incidence of protrud-
ing and mobile left ventricular thrombi and subsequent em-
bolic strokes. However, thrombolysis may occasionally dis-
lodge parts from an already existing left ventricular thrombus
and cause an embolic stroke (20). Ischemic stroke may occur
during other reperfusion therapies (PTCA and CABG), mainly
as a result of embolism or hemodynamic compromise.
Incidence of stroke since the advent of thrombolysis. In
controlled thrombolytic trials (5–9), the reported incidence of
stroke was 0.9% to 1.6%, of which intracranial hemorrhage
represented 0.2% to 0.9%, depending on the type and dose of
agent used. In a collaborative overview of large, randomized
thrombolytic trials (11), an extra 4 strokes/1,000 patients were
associated with thrombolysis versus placebo. An excess risk of
intracranial hemorrhage was observed with tissue-type plas-
minogen activator compared with streptokinase (5–7). Since
the advent of thrombolysis, only a minority of patients with
AMI, those who are mainly low risk patients, have received
thrombolytic therapy (21,22). In a community-based study
(23), the overall stroke rate during the hospital period was
1.6% among patients with AMI treated with thrombolysis
versus 2.2% among the 75% of patients excluded from throm-
bolytic therapy for a variety of reasons.
Comparison of stroke incidence between periods. The re-
cent megatrials provide extensive data on stroke incidence,
type and outcome after thrombolysis among patients with
AMI. However, these trials include only patients treated with
thrombolysis. Yet, the majority of patients with AMI in the
community are not treated with thrombolysis (23). A main
advantage of the present report is the opportunity to evaluate
overall stroke incidence in two unselected cohorts of patients
with AMI, separated by a decade, in which management
changed substantially. Both of our cohorts, although small
compared with the large thrombolysis cohorts, include consec-
utive patients with AMI admitted to most (during 1981 to
1983) and all (during 1992 to 1994) CCUs operating in Israel.
One of the important findings of the present study is that the
overall incidence of early cerebrovascular events was similar
and did not increase during the 1992 to 1994 period, although
thrombolysis was provided to almost 50% of patients with AMI
versus one decade earlier.
Prognosis after stroke. Stroke complicating AMI adversely
affects outcome. In the prethrombolytic era, an estimated
threefold increase in in-hospital and long-term mortality rates
was observed among patients with versus those without a
cerebrovascular event (2–4). Intracerebral hemorrhage in-
duced by thrombolytic therapy is associated with a higher
mortality rate. In the GUSTO-1 megatrial (8), 17% of patients
with a nonhemorrhagic stroke died versus 60% with an intra-
cerebral hemorrhage. In our two cohorts of patients, the
mortality rates of patients sustaining any cerebrovascular event
were increased about threefold. The comparable mortality
rates may reflect the continued dominance of ischemic stroke
over intracerebral hemorrhage in the 1990s. Contrary to the
dramatic change in the management of AMI during the past
decade, little change occurred in the management of ischemic
stroke or intracerebral hemorrhage. Accordingly, although the
survival of patients with AMI improved substantially, the
prognosis of those sustaining a stroke remained poor. Recent
advances and an increasingly active approach in the manage-
ment of both acute ischemic stroke and intracerebral hemor-
rhage may potentially lead to a better prognosis for these
patients (24,25).
Study limitations. We compared the rates of cerebrovas-
cular events complicating AMI within the CCU only. However,
most cases of stroke, as demonstrated in our 1981 to 1983
cohort, occur early during the hospital period in the CCU, and
any increase in intracranial hemorrhage from thrombolysis
would be expected in this time period (7). Rates may possibly
be somewhat underestimated in our cohorts because of an
incomplete recognition of minor cerebrovascular events. How-
ever, comparison is facilitated by the fairly similar demo-
graphic and clinical characteristics, diagnostic criteria and
methods in both cohorts. Because of the small number of
patients with a cerebrovascular event in the 1992 to 1994
period and their incomplete evaluation, we were not able to
report on the rate of ischemic versus hemorrhagic strokes.
However, left ventricular thrombi on transthoracic echocardi-
ography were evident in one-third of patients with stroke in
this cohort, and the type of stroke was ischemic in those
patients examined by brain imaging, suggesting a high rate of
cardioembolic ischemic strokes in the unselected 1992 to 1994
cohort.
Clinical implications. During the past decade, thrombo-
lytic therapy and new therapeutic modalities reduced mortality
and morbidity after AMI. With these therapies, concerns were
raised that the incidence of stroke in clinical practice will
increase as a result of more intracranial hemorrhages. Never-
theless, our results show that the improvement in outcome
after AMI in the 1990s compared with the 1980s was not
accompanied by a higher rate of early cerebrovascular events
and that embolic cerebral infarction remains the common
stroke type. Further studies are needed to find new variables
that may identify patients prone to develop hemorrhagic
strokes from thrombolysis and to assess the benefit of imme-
diate PTCA in such high risk patients.
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Appendix
Participating Centers, Directors of Cardiac
Departments and Responsible Physicians for the
Israeli National Thrombolytic Survey
Assaf Harofeh Hospital, Zerifin: Zwi Schlesinger, MD, Hady Faibel, MD;
Barzilai Medical Center, Ashkelon: Leonardo Reisin, MD, Jamal Jafari, MD;
Beilinson Medical Center, Petach Tikvah: Samuel Sclarovsky, MD, Boris Stras-
berg, MD, Eldad Rehavia, MD; Bikur Cholim Hospital, Jerusalem: Shlomo Stern,
MD, Andre Keren, MD, Shmuel Gottlieb, MD; Bnei-Zion Medical Center, Haifa:
Edward Abinader, MD, Ehud Goldhammer, MD; Carmel Hospital, Haifa: Basil
S. Lewis, MD, Nabil Mahul, MD, David Hallon, MD, Moshe Flugelman, MD;
Carmel Hospital and “Lin” Medical Clinic, Haifa: Abraham Palant, MD, Chen
Shapira, MD; Central Emek Hospital, Afula: Tiberiu Rosenfeld, MD, Nahum
A. Friedberg, MD; Hadassah, Ein-Kerem, Medical Center, Jerusalem: Mervyn
S. Gotsman, MD, Yonatan Hasin, MD, Chaim Lotan, MD; Hadassah, Mount
Scopus, Jerusalem: Teddy A. Weiss, MD, Shimon Rosenheck, MD; Hasharon
Hospital, Petach Tikvah: Izhar Zahavi, MD, Menachem Kanetti, MD; Hillel
Yaffe Hospital, Hadera: Benyamin Pelled, MD, Fatchy Daka, MD, Magdalah
Rashmi, MD; Ichilov Hospital, Sourasky Medical Center, Tel Aviv: Shlomo
Laniado, MD, Arie Roth, MD; Josephtal Medical Center, Eilat: Alen Gelvan,
MD; Kaplan Hospital, Rehovot: Avraham Caspi, MD, Oskae H. Kracoff, MD,
Michael Oettinger, MD; Meir Hospital, Sapir Medical Center, Kfar Saba:
Daniel David, MD, Hana Pauzner, MD; Rambam Medical Center, Haifa:
Walter Markiewicz, MD, Haim Hammerman, MD, Boaz Benari, MD;
Rebecca Sieff Medical Center, Safed: Alon T. Marmor, MD, David Blondheim,
MD; Shaare Zedek Medical Center, Jerusalem: Dan Tzivoni, MD, Jonathan
Balkin, MD, Mark Klutstein, MD; Sheba Medical Center, Tel Hashomer:
Elieser Kaplinsky, MD, Hanoch Hod, MD; Soroka Medical Center, Beersheva:
Natalio Kristal, MD, Alexander Battler, MD, Amos Katz, MD, Arie Gilutz,
MD; Western Galilee Hospital, Naharia: Nathan Roguin, MD; Wolfson
Medical Center, Holon: Yehezkiel Kishon, MD, Ron Narinsky, MD (de-
ceased), Michael Kriwiski, MD. Coordinating Center of the National Israeli
Thrombolytic Survey: S. Behar, MD, Neufeld Cardiac Research Institute,
Sheba Medical Center, Tel Hashomer.
SPRINT Study Group
Executive Board. Henry N. Neufeld, MD, Chairman (deceased); Jacob
Agmon, MD, Vice-Chairman; Solomon Behar, MD, Uri Goldbourt, PhD,
Henrietta Reicher-Reiss, MD, Edward Abinader, MD, Jacob Barzilay, MD,
Natalio Cristal, MD, Yaacov Friedman, MD, Nissim Kauli, MD, Yehezkiel
Kishon, MD, Abraham Palant, MD, Benyamin Peled, MD, Leonardo Reisin,
MD, Egon Riss, MD (deceased), Zwi Schlesinger, MD, Izhar Zahavi, MD,
Monty Zion, MD.
Participating Centers, Principal Investigators and Physicians. Assaf Harofeh
Hospital, Zerifin: Principal Investigator, Zwi Schlesinger, MD, Physician, Moshe
Algom, MD; Barzilai Medical Center, Ashkelon: Principal Investigator, Leonardo
Reisin, MD, Physician, Newton Yalom, MD; Beilinson Medical Center, Petach
Tikvah: Principal Investigator, Yaacov Friedman, MD; Carmel Hospital and
Medical Clinic “Lin” Haifa: Principal Investigator, Abraham Palant, MD, Physi-
cian, Ephraim Mayer, MD; Central Emek Hospital, Afula: Principal Investigator,
Jacob Barzilay, MD, Physician, Lev Bloch, MD; Hasharon Hospital, Petach
Tikvah: Principal Investigator, Izhar Zahavi, MD, Physician, Menachem Katz,
MD; Hillel Yaffe Hospital, Hadera: Principal Investigator, Benyamin Pelled, MD,
Physician, Zakki Abu-Moukh, MD; Kaplan Hospital, Rehovot: Principal Investi-
gator, Nissim Kauli, MD, Physician, Emanuel Liebman, MD; Rambam Medical
Center, Haifa: Principal Investigator, Egon Riss, MD (deceased), Physician, Jamil
Hir, MD; Bnei Zion Center, Haifa: Principal Investigator, Edward Abinader, MD,
Acting Principal Investigator, Ehud Goldhammer, MD, Physician, Salim Maalouf,
MD; Shaare Zedek Medical Center, Jerusalem: Principal Investigator, Monty Zion,
MD, Physicians, David Rosenmann, MD, Jonathan Balkin, MD; Sheba Medical
Center, Tel Hashomer: Principal Investigator, Henrietta Reicher-Reiss, MD;
Wolfson Medical Center, Holon: Principal Investigator, Yehezkiel Kishon, MD,
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